introduction
Neoadjuvant chemotherapy, as opposed to adjuvant chemotherapy, is used to enable breast conserving surgery (BCS) in patients with large tumor size [1] . Long-term followup from six randomized trials indicates no survival benefit for neoadjuvant over adjuvant chemotherapy and because of this, in many countries (e.g. USA) the standard of care remains conventional adjuvant chemotherapy [2] [3] [4] [5] . However, neoadjuvant chemotherapy can cause tumor shrinkage, which enables a proportion of patients to be eligible for BCS, thus avoiding mastectomy. Moreover, patients who achieve a complete pathological response ( pCR) have a better long-term survival [3, 6, 7] . This clinical utility of neoadjuvant chemotherapy is becoming increasingly more common for operable breast cancer [1, 3, [8] [9] [10] . In addition, clinical studies demonstrate that neoadjuvant chemotherapy increases BCS rate in comparison to adjuvant only chemotherapy [3, 4] .
Overall, this background emphasizes that the primary aim of preoperative chemotherapy, in the context of daily practice, is to increase the likelihood of breast conservation in patients with large tumors. Nevertheless, most trials suggest that a significant subset of patients will not be eligible for BCS after neoadjuvant chemotherapy. This relates to both poor chemosensitivity of the tumor and large tumor size. For this subset of patients, neoadjuvant chemotherapy was provided in excess and did not lead to significant benefit. Based on this background, there is a need to identify at diagnosis which patients will not be candidates for BCS. Developing such a predictor could allow frontline treatment with surgery or other neoadjuvant therapy for tumor shrinkage. Recently, a nomogram using standard clinicopathologic factors was developed and validated for discriminating BCS eligibility and demonstrated a concordance index [c-index; area under the curve (AUC) from receiver's operating characteristic (ROC) analysis] of 0.71 for patients receiving neoadjuvant anthracycline plus paclitaxel [11] . Although this nomogram was a first step in the prediction of BCS, it did not present high metric performance and is therefore not currently used as decision criteria. New tools are therefore needed to predict which patients are eligible for neoadjuvant chemotherapy for breast conserving purposes.
Genomic signatures with significant prognostic capability have been developed and validated for prediction of recurrence in the adjuvant setting [12] . Within the neoadjuvant chemotherapy setting, the 21-gene assay and the 70-gene signature have been shown to predict pCR; however, whether their respective performances increase predictive accuracy above the use of standard clinicopathologic factors has not been examined [13] [14] [15] . Furthermore, the use of a genomic signature to predict BCS eligibility as well as assess additive accuracy to clinicopathologic factors has not been reported.
Breast Cancer Index (BCI), a combination of the two-gene ratio HOXB13 : IL17BR (H : I) and the five-gene molecular grade index, stratifies early-stage estrogen receptor (ER) + lymph node (LN) − breast cancer patients into three categorical risk groups and provides a continuous assessment of individual risk of distant recurrence [16, 17] . In this study, we assess the performance of BCI to predict chemosensitivity based on pCR and BCS eligibility within a retrospective study from a single institution. In addition, assessment of the additive accuracy of this genomic signature with existing clinicopathologic factors is reported.
methods patients and biopsy collection
This was a blinded retrospective analysis of clinical cases (N = 196) from a single institution (Institut Gustave Roussy, Villejuif, France) in breast cancer patients treated with neoadjuvant chemotherapy. Patients were selected to have presented an infiltrating breast carcinoma treated with chemotherapy followed by surgery. All patients received at least four cycles of neoadjuvant anthracycline and/or taxane. Patients receiving neoadjuvant trastuzumab treatment were not included in the trial. None of the patients who underwent neoadjuvant chemotherapy were eligible for a frontline breast conservative surgery. Except for patients with T4 lesion, all patients who underwent neoadjuvant chemotherapy at Institut Gustave Roussy were informed and agreed to subsequent breast conservation in case of tumor shrinkage. Patients who preferred mastectomy were treated frontline with surgery. Among the 196 patients captured to have received frontline chemotherapy followed by surgery, 42 patients actually presented a stage IV disease and were excluded from this study. ER status and progesterone receptor (PR) status were determined by immunohistochemistry (IHC). HER2 status was assessed by IHC and FISH only for score 2+. The study was approved by the institution's ethics board. Patients had signed informed consent allowing research projects on their tumor samples.
RNA extraction and gene expression analysis
RNA was extracted from formalin-fixed paraffin-embedded tumor samples using three 7-μm sections and a real-time RT-PCR assay was completed at bioTheranostics, Inc. (San Diego, CA) to generate a BCI score and risk group categorization as previously described [17] . Cases were excluded if there was insufficient RNA (average cycle threshold for normalizing genes during RT-PCR > 28.5). RT-PCR was successful in all but four cases. After excluding these four patients, the overall population for analysis was finally 150 patients.
statistical analysis
The predefined end points were pCR and BCS. pCR was defined as no residual invasive or in situ cancer in breast and lymph nodes. Both pCR and BCS were retrospectively assessed from medical files. The significance of the relationship between demographic variables and clinical/pathological factors with BCI risk groups were calculated with Fisher's exact test for categorical variables and analysis of variance (ANOVA) for continuous variables. Univariate and multivariate logistic regression was used to evaluate whether clinical/pathological factors and BCI are significant predictors of pCR or BCS. C-index, which is equivalent to the nonparametric AUC of ROC curve, was derived from logistic regression. Comparison of two c-indices (AUCs) was done using Delong's nonparametric approach [18] . All statistical analyses were carried out using the R statistical software package, version 2.12.2 (www.r-project.org).
results

patient characteristics and BCI distribution
Of the 196 patients initially identified to have been treated with chemotherapy followed by surgery, 4 had insufficient RNA and 42 were excluded given the presence of a distant metastasis at diagnosis, therefore yielding 150 assessable cases. Patient characteristics are summarized in Table 1 For BCI risk distribution among the 150 patients, 64 (42%) of patients were classified as low risk versus 52 (35%) and 34 (23%) as intermediate and high risk, respectively (Table 1) . BCI risk categories were significantly associated with tumor grade (P < 0.0001) and ER/PR status (P = 0.0013) ( Table 1) . Within tumor subtypes, the BCI low-risk category was significantly associated with ER + /HER2 − tumors (53 % of patients categorized for low risk) (P = 0.0003). BCI intermediate/high risk was significantly associated with triplenegative tumors (ER − /PR − /HER2 − ) (83 % of patients having intermediate or high-risk BCI score) (P = 0.0001).
BCI as a predictor for pCR
A total of 22 of the 150 patients achieved pCR (15%). BCI was associated with an 18-fold increased likelihood of pCRs Table 1 ). For tumor subtypes, there were 4 pCRs for 94 ER + /HER2 − tumors (4%), 5 pCRs for 12 HER2 + tumors (42%) and 13 pCRs for ER − /PR − /HER2 − tumors (33%) tumors (Table 2 ). Risk stratification of BCI was significantly associated with pCR in HER2 − tumors (P < 0.0001) and ER + /HER2 − tumors (P = 0.0492) with no pCRs observed within low risk for these subtypes. The negative predictive value (NPV) of BCI to predict pCR was 98.4 % and 100 % for both ER + /HER2 − , HER2 − and ER − /PR − /HER2 − tumors. (Table 3) . Within a multivariate analysis which included these clinicopathologic parameters, BCI remained significantly associated with pCR both as a continuous score (P = 0.0013) and as categorized risk groups with an odds ratio of 34 for high vs low risk (P = 0.0055, Table 3 ). A plot of probability of pCR as a function of BCI indicates that patients with a high-risk BCI have a range of ∼20 % to 65 % predicted probability of pCR ( Figure 1A ). The 
BCI as a predictor for BCS
For all patients, BCS as opposed to mastectomy was completed for 48 patients (32%). BCS eligibility was significantly stratified by BCI with a more that threefold increase in the percentage of patients undergoing conservative surgery within intermediaterisk or high-versus low-risk groups (Table 1 , P = 0.0002). Within HER − , ER + /HER2 − and ER − /PR − /HER2 − subtypes, risk stratification by BCI was significantly associated with BCS (P = 0.0001, 0.0162, and 0.0116, respectively; Table 2 ). Table 4 summarizes the univariate and multivariate analyses for BCS. In univariate analysis, pathological tumor size, tumor grade, ER, PR and BCI were all significantly associated with BCS (Table 4) . NPV of BCI to predict BCS was 86 % (Table 1) . In multivariate analysis, tumor size and BCI risk groups remained significantly associated with BCS with an odds ratio of 5.78 for high-versus low-risk groups (P < 0.0001 and P = 0.0022, respectively). A plot of probability of BCS as a function of BCI indicates that patients with intermediate-or high-risk BCI have a range of ∼30 % to 60 % predicted probability of BCS ( Figure 1B ). c-index was calculated to determine the overall classification power of BCI to discriminate BCS vs no BCS. For all patients, using clinicopathologic factors only (ER, PR, HER2, tumor size and grade), the c-index was 0.788 and inclusion of BCI significantly increased the c-index to 0.843 (P = 0.025). For tumor subtypes, inclusion of BCI significantly increased the c-index from 0.785 to 0.842 for HER2 − tumors (P = 0.023), from 0.679 to 0.849 for ER − /PR − /HER2 − tumors (P = 0.015) and nonsignificantly increased ER + /HER2 − tumors from 0.819 to 0.858. discussion BCI was a significant predictor for both tumor responsiveness (chemosensitivity) and successful BCS for breast cancer patients treated with neoadjuvant chemotherapy. Previously, BCI was developed and validated as a prognostic tool for ER + LN − breast cancer patients by a retrospective analysis of samples from a randomized clinical trial of adjuvant tamoxifen treatment versus untreated [17] . Using previously defined BCI risk groups of prognosis for adjuvant tamoxifen treatment, BCI performance was assessed for predicting pCR and BCS end points for patients treated with neoadjuvant chemotherapy [19] . Patients in the BCI high-versus low-risk groups had a 34 and 5.8 greater likelihood of achieving a pCR and BCS eligibility, respectively, after taking into consideration standard clinicopathologic factors.
Within the clinical setting, neoadjuvant therapy is used to assess chemotherapy response, eligibility for BCS and to obtain long-term disease-free and overall survival [1, 9] . Results from randomized clinical trials demonstrate that patients treated with neoadjuvant chemotherapy who also achieved a pCR have superior disease-free and overall survival versus those that did not [3] . In addition, a retrospective analysis of 1731 patients, breast cancer patients who achieved a pCR versus those who did not, had superior overall survival irrespective of hormonal status [6] . Herein, we demonstrate a statistically significant association between BCI risk groups in ER + /HER2 − (P = 0.0492) and a significant trend in ER − patients with pCR (P = 0.105; N = 47). BCI's strength to predict pCR suggests that BCI may also predict patient benefit for chemotherapy. For example, in the low-risk category, 98 % of patients did not achieve a pCR suggesting that patient benefit from chemotherapy would be minimal. Conversely, within the high-risk group, 29 % of patients achieved a pCR suggesting a greater likelihood to obtain benefit from chemotherapy. Studies that directly assess this hypothesis are needed.
Other prognostic gene expression signatures, such as the 21-gene assay and 70-gene signature, have the ability to predict pCR following neoadjuvant chemotherapy; however, there is no c-index information regarding the additive accuracy of these signatures beyond standard clinicopathologic parameters [13] [14] [15] . Reporting evidence that genomic scores improve performance as compared with standard clinical characteristics is becoming a major challenge in the field of personalized medicine. Recently, investigators reported a composite genomic signature that significantly increased the predictive utility of a model, which incorporated clinicopathologic factors [20] . We demonstrate here, within the clinically relevant HER2 − tumor type (i.e. patients who would receive chemotherapy and not the combination of chemotherapy plus trastuzumab), that BCI significantly increased the c-index beyond clinicopathologic factors. This significant increase in accuracy coupled to the known interoperator reproducibility for assessing tumor grade (reported Kappa values range between 0.4 and 0.73) suggests that BCI could be a useful tool for clinicians to use for the assessment of chemosensitivity [21] [22] [23] . A principle advantage of neoadjuvant therapy is to increase the likelihood for a patient to be eligible for BCS. However, a 32 % rate of BCS reported within this study, as well as rates of 38%-68 % reported for other cohorts [3, 20] , suggests that predictive tools are needed to assess the likelihood of BCS for patients treated with chemotherapy. A prediction of a low probability for BCS eligibility would be clinically useful. Indeed, these patients could be treated either with mastectomy or with new compounds frontline. In this study, a significant proportion of the patients were classified as low risk (42%, N = 64) and only 14 % of these patients underwent BCS after neoadjuvant chemotherapy. This data suggest that BCI may be clinically useful in identifying the proportion of patients who will not be candidates for BCS. Interestingly, none of the biological parameters, except BCI was able to predict BCS. Previously, a nomogram was reported to predict BCS eligibility for anthracycline plus taxane neoadjuvant therapy [11] . This model, which included clinicopathologic parameters of ER status, tumor size and grade, multicentricity and histological type, had a c-index of 0.71 for an independent test set of 109 patients [11] . We demonstrate that the addition of BCI significantly increases the predictive accuracy for BCS eligibility beyond clinicopathologic factors. For example, in the clinically relevant HER2 − tumor type, BCI significantly increased the c-index from 0.785 to 0.842. To extend these findings to a clinically practical tool, an individual patient BCI score could be generated that is associated with a given probability of being eligible for BCS when treated with neoadjuvant chemotherapy (Figure 1B) . A prospective clinical study will aim at validating such findings.
Although this study suggests that BCI has strong predictive value, this study presents several limitations. The most important relates to the patient selection. Indeed, in this retrospective analysis, patients were not selected based on ER or HER2 expression for the indications of neoadjuvant chemotherapy. This could have increased the predictive strength of BCI given that this biomarker was initially developed and validated in ER + node-negative patients. Nevertheless, our study suggests that BCI is predictive within each molecular class and could therefore be useful independently to ER expression. Additionally, BCI risk stratifications were developed and validated in ER + LN − patient populations and this study represents an exploratory extension of these risk categories to LN + and ER − patient populations. Future studies are planned to further validate BCI within these additional patient populations.
In conclusion, we report here that BCI predicts pCR and BCS eligibility for patients treated with neoadjuvant chemotherapy. BCI significantly increases the accuracy for predicting both pCR and BCS eligibility beyond standard clinicopathologic factors. These findings are clinically suggestive of the use of BCI as a predictor of both chemosensitivity and successful BCS for a patient who is a candidate for neoadjuvant chemotherapy. 
